TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00381329

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing (MI)
Description: MI is an empirically supported, client-centered, directive method for matching counseling to an individual's readiness to change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Brief Advice (SBA)
Description: SBA includes the administration of scripted, brief cessation counseling that follows standard health care smoking cessation guidelines.
Study: NCT02300142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 Vaccine (30μg of each antigen)
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 Vaccine (30μg of each antigen)
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 Vaccine (30μg of each antigen)
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 Vaccine (60μg of each antigen)
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 Vaccine (60μg of each antigen)
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 Vaccine (60μg of each antigen)
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (25μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (25μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (50μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (50μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (75μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (75μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
Study: NCT00511654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW823296 tablet
Description: GW823296 immediate release tablets will be available as white film-coated tablets containing 5 milligrams (mg) and 20 mg of GW823296 for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW823296 tablet
Description: GW823296 immediate release tablets will be available as white film-coated tablets containing 5 milligrams (mg) and 20 mg of GW823296 for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW823296 matching placebo
Description: Matching placebo tablets will be identical in appearance to the GW823296 tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW823296 matching placebo
Description: Matching placebo tablets will be identical in appearance to the GW823296 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered as 5 milliliter (mL) of an intravenous solution for oral application (5 mg/5 mL, Dormicum).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam will be administered as 5 milliliter (mL) of an intravenous solution for oral application (5 mg/5 mL, Dormicum).
Study: NCT00369161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus (RAD001)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus (RAD001)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Study: NCT00942539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Intravenous infusion of 0.05 mg/kg of Midalolam
Study: NCT02782754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced dose of radiotherapy
Study: NCT00123656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: esomeprazole dosed qam for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone
Description: fluticasone dosed 220 mcg 2 puffs swallowed BID for 8 weeks
Study: NCT03972241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: foot insole
Description: arch support and toe extension
Study: NCT03734445

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin Supplement
Description: Subjects will be randomly allocated to a supplementation of vitamin C 1000mg, vitamin D 400 IU and zinc 10 mg or an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomly allocated to a supplementation of an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
Study: NCT02665923

Intervention type: OTHER
Intervention: Gastric ultrasound
Description: Ultrasound of abdomen to assess antral volume
Study: NCT04418089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: The administration of Simvastatin 40 mg in addition to neoadjuvant chemoterapy CAF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: The administration of Placebo capsule 40 mg in addition to neoadjuvant chemoterapy CAF
Study: NCT03922841

Intervention type: OTHER
Intervention: Pleural disease management
Description: History, physical examination, pleural drainage, lab/radiographic investigations
Study: NCT04606875

Intervention type: DIAGNOSTIC_TEST
Intervention: Campbell Score
Description: The Campbell Score is a blood based assessment of inflammatory and immunologically associated markers that is currently in development as a means of predicting suicidal ideations.

Intervention type: DIAGNOSTIC_TEST
Intervention: Campbell Score
Description: The Campbell Score is a blood based assessment of inflammatory and immunologically associated markers that is currently in development as a means of predicting suicidal ideations.

Intervention type: DIAGNOSTIC_TEST
Intervention: Campbell Score
Description: The Campbell Score is a blood based assessment of inflammatory and immunologically associated markers that is currently in development as a means of predicting suicidal ideations.
Study: NCT04066322

Intervention type: PROCEDURE
Intervention: system treatment and surgery
Description: to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to receive Synchronous resection of primary tumor and metastasis. after surgery, the investigator decide further treatments.

Intervention type: OTHER
Intervention: system treatment
Description: to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to continue take system treatment.
Study: NCT01111682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: 0.9% normal saline infusion and boluses of mannitol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline
Description: 3% hypertonic saline continuous infusion, with intermittent boluses as needed
Study: NCT00897975

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: red yeast rice
Description: 600 mg 3 capsules bid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: red yeast rice
Description: 600 mg 3 capsules bid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: red yeast rice
Description: 600 mg 3 capsules bid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: red yeast rice
Description: 600 mg 3 capsules bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phytosterol
Description: phytosterol 450 mg 2 tabs bid with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phytosterol
Description: phytosterol 450 mg 2 tabs bid with food

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic lifestyle program
Description: TLC - 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic lifestyle program
Description: TLC - 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03309124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mashed potatoes
Description: Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fried French fries
Description: Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
Study: NCT00897975

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03309124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal skipping
Description: No food given
Study: NCT06106074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, oral
Study: NCT04539379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetolol
Description: intravenous infusion
Study: NCT05926128

Intervention type: DRUG
Group type: OTHER
Intervention: Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
Description: Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment with a scheduled molecular monitoring until month 24.
Study: NCT01266993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix (GSK134612 vaccine)
Description: Intramuscular, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menjugate
Description: Intramuscular, 1 dose
Study: NCT00114309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131-I-TM-601
Description: 131I-TM601, in solution, delivered intracavitarily following surgical resection 3 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-TM601
Description: 131I-TM601, in solution, delivered intracavitarily following surgical resection 6 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
Study: NCT00253786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial therapy
Description: Blood glucose control: HbA1c \< 6.2% Blood pressure control: SBP \< 125 mmHg, DBP: \< 75 mmHg Lipid profile: T-cho \< 180 mg/dl, LDL-cho \< 100 mg/dl, HDL-cho \>40 mg/dl Dietary intervention: TDEI \< 30 kcal/kg/day, sodium \< 5 g/day, protein \< 0.8 g/kg/day Pharmacological intervention: ACE-Is or ARBs, HMG-CoA reductase inhibitors, multivitamins Instruction by co-medicals: Taking medicines, smoking cessation, nutrition care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial therapy
Description: Blood glucose control: HbA1c \< 6.2% Blood pressure control: SBP \< 125 mmHg, DBP: \< 75 mmHg Lipid profile: T-cho \< 180 mg/dl, LDL-cho \< 100 mg/dl, HDL-cho \>40 mg/dl Dietary intervention: TDEI \< 30 kcal/kg/day, sodium \< 5 g/day, protein \< 0.8 g/kg/day Pharmacological intervention: ACE-Is or ARBs, HMG-CoA reductase inhibitors, multivitamins Instruction by co-medicals: Taking medicines, smoking cessation, nutrition care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Blood glucose control: HbA1c \< 6.9% Blood pressure control: SBP \< 130 mmHg, DBP: \< 80 mmHg Lipid profile: T-cho \< 200 mg/dl, LDL-cho \< 120 mg/dl, HDL-cho \>40 mg/dl, Dietary intervention: TDEI \< 25-30 kcal/kg/day, sodium \< 6 g/day, protein \< 1.0 g/kg/day Pharmacological intervention: No restrictions (continuing prior therapy) Instruction by co-medicals: No restrictions (continuing prior therapy)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Blood glucose control: HbA1c \< 6.9% Blood pressure control: SBP \< 130 mmHg, DBP: \< 80 mmHg Lipid profile: T-cho \< 200 mg/dl, LDL-cho \< 120 mg/dl, HDL-cho \>40 mg/dl, Dietary intervention: TDEI \< 25-30 kcal/kg/day, sodium \< 6 g/day, protein \< 1.0 g/kg/day Pharmacological intervention: No restrictions (continuing prior therapy) Instruction by co-medicals: No restrictions (continuing prior therapy)
Study: NCT01387503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Once randomized to Group 1, patients will be enlisted for liver transplantation at the recruiting Center. Prioritization is encouraged as a waiting time of more than 8 months could cause patients' drop-out from the study
Study: NCT03306043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab will be available as 100 mg vial for injection. Subjects will receive three 100 mg SC injections for every 4 Weeks for a total of 5 doses during 20 Week treatment period.
Study: NCT03982888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Stimulation of the nucleus accumbens via 2 electrodes implanted in the brain per patient to reduce self-injurious behaviours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS
Description: Use of the Medtronic DBS device. DBS device consists of 2 parts:~1. DBS lead, a thin wire with 2 electrical contacts implanted into pre-determined brain regions, and~2. Implantable pulse generator, a small device containing the batter and computer source placed under the skin of the chest to generate electrical pulses
Study: NCT02087150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acclarent Eustachian Tube Balloon Catheter (ETBC)
Study: NCT01254175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHPIV3cp45 Vaccine
Description: 10\^5 TCID\^50 of rHPIV3cp45 vaccine, delivered as nose drops

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Placebo vaccine, delivered as nose drops
Study: NCT03146858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin is an anticlotting treatment that targets the other aspect of clot formation known as the coagulation cascade. Enoxaparin or an alternative is recommended as a single does to support PPCI procedure.
Study: NCT00955006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA-016-00-VP
Description: Composed of six DNA plasmids in equal concentrations that encode Gag, Pol, and Nef from clade B (strains HXB2, NL4-3, NY5/BRU) and the HIV-1 Env glycoproteins from clade A (strain 92rw020), clade B (strains HXB2/BaL), and clade C (strain 97ZA012). Vaccine will be administered intramuscularly (IM) in the deltoid via needle-free Biojector.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRCHIVADV014-00-VP
Description: A mixture of 4 recombinant serotype 5 adenoviral replication deficient vectors, each expressing HIV-1 proteins (clade B Gag-Pol fusion, clade A Env, clade B Env, clade C Env). Administered IM via needle and syringe.
Study: NCT02019602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling from mother
Description: A blood sample from the mother will be taken within 24 hours before/after the delivery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling from infant
Description: Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling from umbilical cord
Description: A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.~* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection~* Concentration: 200 mg/ml~* Route of Administration: Subcutaneous Use
Study: NCT00206388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolendric acid
Description: IV, 2mg/m2/dose on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: fixed dose of 25mg/m2/dose days 0-27
Study: NCT03001401

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iDesign
Description: One group will under go standard LASIK using iDesign platform (J\&J, USA). Visual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMILE
Description: The other group will undergo SMILE for treatment refractive error (Carl Zeiss, Germany). isual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
Study: NCT01584830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506)
Description: Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given 3 weeks on/1 week off (160 mg od po.)
Study: NCT04276090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.
Description: Patients will undergo surgical hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.
Description: Patients will undergo surgical hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion pump floxuridine and dexamethasone
Description: Patients will receive infusion of floxuridine (FUDR) and dexamethasone via hepatic artery infusion through the implanted pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion pump floxuridine and dexamethasone
Description: Patients will receive infusion of floxuridine (FUDR) and dexamethasone via hepatic artery infusion through the implanted pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy for colorectal liver metastases
Description: Patients will receive disease-appropriate systemic chemotherapy for colorectal liver metastases (FOLFOX, FOLFIRI, or irinotecan/oxaliplatin, or panitumumab if KRAS/NRAS wild type)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy for intrahepatic cholangiocarcinoma
Description: Patients will receive disease-appropriate systemic chemotherapy for intrahepatic cholangiocarcinoma (gemcitabine/oxaliplatin or gemcitabine alone)
Study: NCT01644396

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Adalimumab
Study: NCT02126436

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Participants will receive a course of traditional Chinese acupuncture. Acupuncture will be pragmatic but strict guidelines will be adhered to including:~using a combination of body and auricular acupuncture, treating the opposite limb to amputation and possibly the residual limb, using auricular acupuncture points such as shen men, sympathetic, points corresponding to the lower limb, using body acupuncture points around the stump (depending on tissue health and the patient), mirroring local and distal points by needling them on the opposite limb, points on the lower back taking a segmental approach to dermatomal pain, including points such as LI4 + LR3, LR3, GV20, SP10, electro-acupuncture may be used, retaining the needles for 20-30 minutes, treating twice weekly for four weeks.
Study: NCT00719212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle